CVS Health beats second quarter expectations, raises full-year profit outlook

Published 01/08/2025, 11:28
© Reuters.

Investing.com -- CVS Health Corporation reported second-quarter earnings that surpassed analyst expectations on Friday. 

Adjusted earnings per share came in at $1.81, significantly above the consensus estimate of $1.46. Revenue for the quarter reached $98.9 billion, exceeding analyst projections of $94.73 billion and representing an 8.4% increase YoY.

The healthcare giant raised its full-year adjusted EPS guidance to a range of $6.30 to $6.40, up from its previous outlook of $6.00 to $6.20, and above the analyst consensus of $6.12. The company also increased its cash flow from operations guidance to at least $7.5 billion, up from approximately $7.0 billion previously. CVS shares edged down 0.7% following the announcement.

The strong quarterly performance was driven by improved operating results in the Health Care Benefits segment, which saw a 39.4% increase in adjusted operating income, and the Pharmacy & Consumer Wellness segment, which posted a 7.6% gain. These improvements were partially offset by a 17.8% decline in the Health Services segment.

"We are encouraged by a second consecutive quarter of solid 2025 results, while we continue to navigate a dynamic environment," said Brian Newman, Chief Financial Officer of CVS Health (NYSE:CVS). "As we execute against our strategic priorities, we remain focused on delivering on our financial commitments and advancing initiatives that create long-term value for our stakeholders."

Despite the strong results, the company revised its GAAP diluted EPS guidance downward to $3.84 to $3.94 from the previous $4.23 to $4.43, reflecting the impact of $833 million in litigation charges recorded during the quarter related to past business practices.

The company’s medical membership stood at 26.7 million as of June 30, 2025, reflecting previously announced membership declines in the individual exchange product line.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.